For neoadjuvant treatment of muscle invasive bladder cancer, are you utilizing durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC?
Were you using gem/cis or ddMVAC more routinely prior to NIAGARA?
Community PollStarted
What is your preferred neoadjuvant regimen for cisplatin-eligible patients with muscle-invasive bladder cancer?
202 physicians have voted
Join Mednetto vote and see how they answered.
3 Answers
Mednet Member
Medical Oncology · University of California Los Angeles, Los Angeles
Answered on
Neoadjuvant Dose Dense MVAC (ddMVAC) has been shown to be safe and effective in MIBC. However, given the different side effect profile compared to cisplatin gemcitabine, especially in terms of bone marrow suppression, cardiotoxicity, and neurotoxicity, the majority of patients are not receiving ddMV...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Mayo Clinic Comprehensive Cancer Center
Answered on
I have used gem cis for the majority of my patients; very occasionally, I have used ddMMVAC for the fit patients. The significant side effects profile for ddMVAC dampens my enthusiasm to use it. I would prefer using gem cis durva over ddMVAC, unless there is a contraindication to adding immunotherap...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Mayo Clinic
Answered on
Our academic practice covers a wide mix of patients, frequently with many comorbidities – this makes it challenging to do dose dense regimens, however, this is certainly a regimen we have used in fitter patients.
Join for free or sign in to see the full answer